Qiang Xu

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea et al. · Blood · 2017 · 1.4K citations · Full text

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu et al. · Clinical Cancer Research · 2014 · 336 citations

Metastatic Breast Cancer, Independent Review Committee, Breast Oncology +13

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi et al. · Blood · 2018 · 323 citations · Full text

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Daniel A. Pollyea, Martin S. Tallman, Stéphane de Botton et al. · Leukemia · 2019 · 235 citations · Full text

Insulin Resistance and Risk of Ischemic Stroke Among Nondiabetic Individuals From the Northern Manhattan Study

Tatjana Rundek, Hannah Gardener, Qiang Xu et al. · Archives of Neurology · 2010 · 168 citations · Full text